Full-Time

Research Chemist

Posted on 8/22/2026

Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

51-200 employees

Develops, acquires, and markets generic drugs

No salary listed

No H1B Sponsorship

Sacramento, CA, USA

In Person

Bachelor's, Master's

Category
Lab & Research (1)
Required Skills
GMP
Biochemistry

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Requirements
  • Proficiency in analytical techniques including high-performance liquid chromatography, gas chromatography, Fourier-transform infrared spectroscopy, ultraviolet-visible spectroscopy, and dissolution testing.
  • Strong understanding of pharmaceutical regulations issued by the Food and Drug Administration and International Council for Harmonisation.
  • Ability to troubleshoot analytical issues and conduct root cause analysis.
  • Strong communication and documentation skills.
  • Excellent attention to detail and organizational skills.
  • Familiarity with Food and Drug Administration and International Council for Harmonisation guidelines, including ICH Q7 and ICH Q10.
  • Knowledge of stability testing guidelines, including ICH Q1A.
  • Ability to stand and work for extended periods in a laboratory environment.
  • Ability to handle chemicals and pharmaceutical substances.
  • Bachelor’s or Master’s degree in Chemistry, Pharmaceutical Sciences, Biochemistry, or a related field.
  • One to five years of experience in a pharmaceutical quality control laboratory.
  • Experience with Good Manufacturing Practices, Good Laboratory Practices, and Good Distribution Practices requirements.
Responsibilities
  • Operate and maintain analytical instruments such as gas chromatography, gas chromatography-mass spectrometry, liquid chromatography-mass spectrometry, ultra-performance liquid chromatography, and high-performance liquid chromatography equipped with ultraviolet-visible, photodiode array, and charged aerosol detection detectors.
  • Calibrate and regularly maintain laboratory equipment to ensure accuracy and precision of results.
  • Assist in developing and validating analytical methods for new products in compliance with regulatory guidelines, including International Council for Harmonisation and Food and Drug Administration guidelines.
  • Perform qualitative and quantitative analyses on raw materials, in-process materials, and finished products using validated methods to ensure compliance with required specifications.
  • Conduct stability studies on products according to International Council for Harmonisation guidelines and stability protocols, and document results for regulatory submissions.
  • Investigate deviations and out-of-specification results, conduct root cause analysis, and implement corrective and preventive actions to address and prevent recurrence.
  • Ensure testing adheres to Good Laboratory Practices, Good Manufacturing Practices, Good Distribution Practices, and other relevant regulatory standards.
  • Implement ICH Q2 (R1) guidelines for method validation and participate in internal and external audits to maintain laboratory compliance.
  • Collaborate with research and development, production, and quality assurance teams to support product development and commercialization efforts.
  • Provide assistance during regulatory inspections.
  • Perform additional tasks assigned by the Chief Scientific Officer.
Nivagen Pharmaceuticals

Nivagen Pharmaceuticals

View

Nivagen Pharmaceuticals develops, acquires, and sells generic prescription drugs and OTC products for the North American market. It leverages global partnerships with FDA-approved manufacturing facilities to deliver high-quality, affordable products and collaborates with the world’s best CROs and CRAMs to develop and manufacture niche generics. The company supports small FDA-qualified manufacturers entering the U.S. market and differentiates itself through its ability to launch new generic products and its strong sales and marketing team, rather than relying on a single manufacturing or development approach. Revenue comes from product development, co-development, acquisitions, in-licensing, and providing sales and marketing services. Nivagen aims to grow its portfolio by forging CRO/CRAM partnerships, acquiring existing products, and expanding its product lineup to capture a larger share of the evolving generic and OTC market in North America.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$26M

Headquarters

Sacramento, California

Founded

2009

Get referred to Nivagen Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PAI Pharma's January 6, 2026 acquisition brings Olympus-backed capital and distribution.
  • Owning the Sacramento site after February 2026 strengthens expansion and regulatory control.
  • Shortage-sensitive injectable demand supports faster commercialization for Nivagen's RTU pipeline.

What critics are saying

  • Nivagen's zinc oxide Class II recall, started October 31, 2025, remains ongoing.
  • California recalled atorvastatin tablets in September 2024 for a carbamazepine mix-up.
  • Repeated cGMP failures or sterile contamination would trigger FDA shutdowns and destroy hospital trust.

What makes Nivagen Pharmaceuticals unique

  • Sacramento's 100,000-square-foot sterile facility makes Nivagen unusually domestic for injectables.
  • Nivagen built over 20 ready-to-use sterile injectables before PAI Pharma's January 2026 acquisition.
  • Its 503B compounding and CDMO services target shortage-driven hospital demand directly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

401 (k) savings plan

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-7%
PE Hub
Jan 6th, 2026
Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals

Olympus-backed PAI Pharma picks up Nivagen Pharmaceuticals. Headquartered in Greenville, South Carolina, PAI is a developer, manufacturer and marketer of oral liquid medicines. * Nivagen operates an aseptic manufacturing facility in Sacramento, California, designed to support the production of IV bags, vials, prefilled syringes, and cartridges * Nivagen was founded in 2009 PAI Pharma, which is backed by Olympus Partners, has acquired Nivagen Pharmaceuticals, Inc, a Sacramento, California-based pharmaceutical company. No financial terms were disclosed. Gain instant access to our expert editorial analysis and in-depth insight. Already have an account? Sign in.

Benzinga
Jan 6th, 2026
PAI Pharma acquires Nivagen to expand US sterile injectable manufacturing amid persistent drug shortages

PAI Pharma, a portfolio company of Olympus Partners, has acquired Nivagen Pharmaceuticals, a California-based pharmaceutical company specialising in ready-to-use sterile injectables. The deal expands PAI's domestic manufacturing capabilities and addresses persistent drug shortages in the US healthcare system. Nivagen operates a state-of-the-art aseptic manufacturing facility in Sacramento, producing IV bags, vials, prefilled syringes and cartridges. The company brings over 20 injectable products to complement PAI's existing sterile portfolio of approximately 10 products in development and four on the market. The acquisition aligns with growing efforts to reshore pharmaceutical production and reduce reliance on foreign supply chains. PAI Pharma was advised by Bourne Partners, Kirkland & Ellis and KPMG, whilst Olympus Partners provided backing for the transaction.

Private Equity Info
Aug 22nd, 2022
Corbel Capital Partners invests into Nivagen Pharmaceuticals, Inc.

Corbel Capital Partners invested in Nivagen Pharmaceuticals (Sacramento, CA, US), a specialty pharmaceuticals business that develops and sells generic and branded prescription drugs.